At 200 mg, 5 of 13 patients reached immunologic remission by week 12; additional PrisMN Phase 2 data are anticipated in 2027 as enrollment continues.

Intel's October 29 earnings report focuses on Q4 guidance, not Q3 results, as markets prioritize future growth signals over current performance.

And the network itself was busy. Arbitrum One's daily active addresses hit a 30-day high on Oct. 21. Falling token, rising activity: the headline writes itself. The headline is the wrong question. On ...